Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sinil Kim

Premium

Mirna Therapeutics has named Sinil Kim as its chief medical officer.

In this role, Kim will be responsible for the clinical development of Mirna’s phase I cancer drug MRX34, as well as other compounds in the firm’s pipeline, Mirna said.

Kim was most recently a senior director at Pfizer, serving as global clinical lead for two renal cancer drug programs. Before that, he was director of clinical oncology at Bristol-Myers Squibb.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.